Shares Magazine
9.85p+0.00 (+0.00%)06 Nov 2025, 16:04
Jump to:
Scancell Holdings PLC Fundamentals
| Company Name | Scancell Holdings PLC | Last Updated | 2025-11-06 |
|---|---|---|---|
| Industry | Biotechnology | Sector | Healthcare |
| Shares in Issue | 1.038 bn | Market Cap | £102.22 m |
| PE Ratio | 0.00 | Dividend per Share | 0 |
| Dividend Yield | 0 | Dividend Cover | 0 |
| EPS | -£0.01 | EPS Growth (%) | 0 |
| PEG | 0 | DPS Growth (%) | 0 |
| Debt Ratio | 0.7045 | Debt Equity Ratio | 0 |
| Asset Equity Ratio | -6.0209 | Cash Equity Ratio | -4.4052 |
| Quick Ratio | 0.6303 | Current Ratio | 0.77 |
| Price To Book Value | 0 | ROCE | 0 |
Scancell Holdings PLC Dividends
| Type | Ex-Date | Pay Date | Currency | Net Dividend | Year Total |
|---|
Scancell Holdings PLC Company Financials
| Assets | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Tangible Assets | £847,000.00 | £1.71 m | £2.25 m | £2.74 m |
| Intangible Assets | £1.62 m | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 |
| Total Fixed Assets | £2.47 m | £1.71 m | £2.25 m | £2.74 m |
| Stocks | 0 | 0 | 0 | 0 |
| Debtors | 0 | 0 | 0 | £647,000.00 |
| Cash & Equivalents | £16.89 m | £14.82 m | £19.92 m | £28.73 m |
| Other Assets | 0 | 0 | 0 | 0 |
| Total Assets | £23.09 m | £23.58 m | £26.86 m | £35.11 m |
| Liabilities | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Creditors within 1 year | £26.80 m | £6.39 m | £7.97 m | £6.65 m |
| Creditors after 1 year | £123,000.00 | £20.69 m | £28.53 m | £27.06 m |
| Other Liabilities | 0 | 0 | 0 | 0 |
| Total Liabilities | £26.93 m | £27.08 m | £36.50 m | £33.71 m |
| Net assets | -£3.83 m | -£3.50 m | -£9.65 m | £1.39 m |
| Equity | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Called up share capital | £1.04 m | £929,000.00 | £819,000.00 | £815,000.00 |
| Share Premium | £82.40 m | £71.93 m | £60.70 m | £60.53 m |
| Profit / Loss | -£15.30 m | -£9.12 m | -£14.30 m | -£6.27 m |
| Other Equity | -£3.83 m | -£3.50 m | -£9.65 m | £1.39 m |
| Preference & Minorities | 0 | 0 | 0 | 0 |
| Total Capital Employed | -£3.83 m | -£3.50 m | -£9.65 m | £1.39 m |
| Ratios | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Debt Ratio | 0 | 0 | 0 | £0.93 |
| Debt-to-Equity | 0 | 0 | 0 | £12.41 |
| Assets / Equity | -6.0209 | -6.0209 | -6.0209 | -6.0209 |
| Cash / Equity | -4.4052 | -4.4052 | -4.4052 | -4.4052 |
| EPS | -£0.01 | -£0.01 | -£0.01 | -£0.01 |
| Cash Flow | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Cash from operating activities | -£6.40 m | -£15.66 m | -£8.14 m | -£10.19 m |
| Cashflow before financing | £3.29 m | -£5.27 m | -£8.89 m | -£11.12 m |
| Increase in Cash | £2.09 m | -£5.09 m | -£8.80 m | -£12.38 m |
| Income | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Turnover | £4.71 m | 0 | £5.27 m | 0 |
| Cost of sales | £238,000.00 | 0 | £525,000.00 | 0 |
| Gross Profit | £4.47 m | 0 | £4.75 m | 0 |
| Operating Profit | -£15.00 m | -£18.27 m | -£11.92 m | -£13.30 m |
| Pre-Tax profit | -£15.30 m | -£9.12 m | -£14.30 m | -£6.27 m |
Scancell Holdings PLC Company Background
| Sector | Healthcare |
|---|---|
| Activities | Scancell Holdings PLC is a clinical-stage biotechnology company developing targeted off-the-shelf active immunotherapies to generate safe and long-lasting tumour-specific immunity for a cancer-free future. iSCIB1+, a product from its DNA ImmunoBody platform (AvidiMab), has demonstrated safe, durable, and clinically meaningful benefit as a monotherapy as well as additional benefit when combined with checkpoint therapies in an ongoing Phase 2 trial in melanoma. Modi-1, the peptide immunotherapy from its Moditope platform, is being investigated in a Phase 2 study in a broad range of solid tumours. In addition, the company has established a subsidiary with the intention to hold and develop an early-stage pipeline of high-affinity GlyMab antibodies targeting tumour-specific glycans. |
| Latest Interim Date | 30 Jan 2025 |
| Latest Fiscal Year End Date | 11 Sep 2025 |
Scancell Holdings PLC Directors
| Appointed | Name | Position |
|---|---|---|
| 2018-08-31 | Ms. Kate Cornish-Bowden | Non-Executive Director |
| 2016-09-16 | Mr. David Eric Evans | Non-Executive Director,Chairman |
| 2014-05-09 | Mr. Peter Vance Allen | Non-Executive Director |
| 2023-02-01 | Dr. John Chiplin | Executive Director,Chairman |
| 2025-09-11 | Professor Linda Gillian Durrant | Executive Director,Chief Executive Officer and Chief Scientific Officer |
| 2024-09-24 | Dr. Richard Morley Goodfellow | Non-Executive Director |
| 2012-12-12 | Mr. Nigel James Forrester Evans | Non-Executive Director,Company Secretary |
| 2013-02-27 | Mr. Thomas Michael Rippon | Non-Executive Director |
| 2019-10-31 | Dr. Matthew Gerrard Winston Frohn | Non-Executive Director |
| 2025-09-16 | Mr. Martin Henry Diggle | Non-Executive Director |
| 2024-02-05 | Dr. Sally Elizabeth Adams | Executive Director,Development Director |
| 2021-07-28 | Dr. Clifford Michael Holloway | Executive Director,Chief Executive Officer |
| 2025-09-11 | Ms. Susan Elizabeth Clement-Davies | Non-Executive Director,Deputy Chairman |
| 2025-09-11 | Dr. Jean Michel Cossery | Executive Director,Chairman |
| 2025-09-11 | Mr. Sath Nirmalananthan | Executive Director,Chief Financial Officer and Company Secretary |
| 2025-09-11 | Dr. Philip John L'Huillier | Executive Director,Chief Executive Officer |
Scancell Holdings PLC Contact Details
| Company Name | Scancell Holdings PLC |
|---|---|
| Address | Robert Robinson Avenue, John Eccles House, Oxford Science Park, Oxford, OX4 4GP |
| Telephone | +44 1865338069 |
| Website | https://www.scancell.co.uk |
Scancell Holdings PLC Advisors
| Nominated Adviser | Panmure Gordon (UK) Ltd |
|---|---|
| Phone | +44 2078862500 |
| Stockbroker | Panmure Gordon (UK) Ltd |
|---|---|
| Phone | +44 2078862500 |
| Financial PR Adviser | FTI Consulting Inc |
|---|---|
| Phone | +44 2037271000 |
| Fax | +44 2037271007 |
| Solicitor | Laytons |
|---|---|
| Phone | (020) 7842 8000 |
| Fax | (020) 7842 8080 |
| Registrar | S.L.C Registrars Ltd |
|---|---|
| Phone | +44 1903706150 |
| Financial PR Adviser | Visible Value LLP |
|---|
| Auditor | Champion Accountants LLP |
|---|---|
| Phone | (01244) 404 420 |
| Fax | (01244) 404 440 |
Most Read
Receive our
daily news email
Subscribe to the latest investing news by entering your email address below
You can opt out at any time.
For five days a week you will get
- The latest company news
- Insight into investment trends
- Round-up of director's buys and sells
- Articles from Shares magazine
Plus more useful investment content and occasional promotional offers.
Market Overview
UK 350 Risers and Fallers
Risers
| Company | Price | % Chg |
|---|---|---|
| Helios Towers PLC | 171.80 | 10.84 |
| Ceres Power Holdings PLC | 377.00 | 1.40 |
| Sainsbury (J) PLC | 355.80 | 5.52 |
| Rs Group PLC | 595.00 | 7.69 |
| Imi PLC | 2,492.00 | 3.75 |
| Antofagasta PLC | 2,746.00 | 3.51 |
Fallers
| Company | Price | % Chg |
|---|---|---|
| Smith & Nephew PLC | 1,242.00 | -10.87 |
| Hikma Pharmaceuticals PLC | 1,522.00 | -14.06 |
| Tbc Bank Group PLC | 3,785.00 | -11.87 |
| Ashmore Group PLC | 170.80 | -8.86 |
| Metlen Energy & Metals PLC | 43.65 | -5.42 |
| Goodwin PLC | 21,200.00 | -9.01 |
Risers/fallers data from previous trading day. Today's data available from 8:15am.